Cutting sugar may not significantly impact hair loss, as DHT and androgenreceptors are the main issues. Effective treatments include finasteride, dutasteride, RU58841, and minoxidil, often combined with microneedling.
The conversation discusses maintaining hair regrowth using minoxidil and finasteride and whether using gt20029, which degrades androgenreceptors, would affect this. Fluridil, a similar treatment, can disable over 90% of active androgenreceptors.
Clascoterone shows promising results for hair regrowth in men with androgenetic alopecia, with potential FDA approval by 2026. It acts as a topical androgenreceptor blocker, offering a new treatment option with minimal side effects compared to existing treatments like finasteride.
RU58841 is discussed as a hair loss treatment, with concerns about its effectiveness diminishing after two years due to androgenreceptor upregulation. The user is hesitant to start using it, fearing it may worsen their condition over time.
KX-826 is being discussed for hair loss treatment, with users debating between 0.5% and 0.9% solutions and foam. Some report side effects like headaches, while others see no changes; it blocks androgenreceptors without reducing DHT levels.
PP405 and GT20029 are new hair loss treatments with different mechanisms from traditional options like Minoxidil and Finasteride. PP405 targets hair follicle stem cells to reactivate growth, while GT20029 works as an androgenreceptor deleter, both requiring ongoing use for effectiveness.
RU58841 worsened hair condition, causing thinning and unusual patterns. The user stopped using it two months ago but hasn't seen recovery, and there's speculation about androgenreceptor upregulation.
Pyrilutamide is a selective AR antagonist with a high binding affinity, making it effective in competing with DHT for androgenreceptors. The 1% concentration is more effective than the 0.5%, but the latter may suffice for mild hair loss; the drug is considered a good option for those avoiding 5AR blockers due to side effects.
Exploring hair loss treatments beyond DHT, including Minoxidil, pyruvate, Gt20029 targeting androgenreceptors, and vasodilators. Other options like Kx826, adenosine signaling, growth factor topicals, and microneedling are also discussed.
The conversation discusses doubts about the effectiveness of topical finasteride for hair loss, suggesting that DHT could be produced elsewhere in the body and affect the scalp. It proposes that androgenreceptor antagonists like spironolactone and clascoterone might be more effective as they could prevent this potential bypass mechanism.
He Shou Wu (Fo Ti) extract was found to prolong the hair growth phase, inhibit 5-alpha-reductase (like finasteride), reduce androgenreceptors, and increase growth factors, potentially outperforming minoxidil in recovering hair follicle size after DHT exposure. Two compounds, emodin and TSG, are identified as responsible for these effects and warrant further investigation.
Fluridil, also known as Topilutamide or Eucapil, is discussed as a treatment for hair loss. It is noted as an androgenreceptor antagonist, not a vasodilator.
The conversation discusses how Caucasian men are more likely to experience hair loss due to genetic predisposition, with factors like the androgenreceptor on the X chromosome playing a significant role. The user also expresses confusion about the evolutionary reasons for hair loss, especially in colder climates where it would seem beneficial to retain hair for warmth.
KX-826 is a potential hair loss treatment, with users discussing its effectiveness compared to finasteride and concerns about its trial results. Some users express skepticism about new treatments, while others discuss the potential of androgenreceptor degraders and the need to manage drug resistance.
Breezula shows promise in stabilizing hair loss and potentially promoting regrowth at the one-year mark, offering hope for those who can't tolerate 5AR inhibitors. Its local targeting of androgenreceptors could be a significant advancement if it avoids systemic side effects.
The user is seeking advice on improving their hair loss treatment regimen, considering changes to their topical solution, and is curious about others' daily routines and recommendations for medications and supplements. They are contemplating switching Tretinoin for Tazarotene, Latanoprost for Bimatoprost, and possibly adding Alfatradiol, Topical Melatonin, or a topical androgenreceptor antagonist.
The conversation discusses a last-resort hair loss treatment combining topical finasteride, minoxidil, melatonin, and progesterone, with claims that topical finasteride can inhibit up to 52% of scalp DHT. One reply clarifies that progesterone is not an anti-androgen but has anti-androgenic properties because it competes with androgens for receptors.
Minoxidil may suppress androgen activity in hair follicles, potentially aiding in hair growth and prostate cancer treatment. Users discuss the effectiveness of minoxidil and finasteride for hair maintenance and regrowth, with some preferring topical applications over oral due to safety concerns.
A 23-year-old has been using finasteride, dutasteride, and spironolactone to combat hair loss and hormonal acne, with mixed results and concerns about side effects. The user is experimenting with spironolactone despite its potential risks, hoping for skin and body hair improvements.
Minoxidil is not an anti-androgen; it is a growth stimulator and does not lower DHT like finasteride or dutasteride. Minoxidil can cause side effects like facial swelling and anxiety due to its vasodilator properties.
The conversation lists hair loss treatments including finasteride, dutasteride, RU58841, pyrilutamide, breezula, and fluridil, and suggests ketoconazole as another option. Some users warn against using certain treatments like cyproterone acetate, bicalutamide, and spironolactone due to their strong anti-androgen effects and potential impact on masculinity.
User asks about topical spironolactone experience. Two studies show it as promising anti-androgen treatment, with 5% cream available on Minoxidilmax website.
People discussed their experiences with anti-androgens for hair loss, mentioning side effects like chest pains with RU58841 and skepticism due to lack of safety data, while considering Fluridil as a potential addition to treatment. Some users expressed reluctance to use these chemicals.
The conversation discusses alternatives to RU58841 for hair loss treatment, with suggestions including topical spironolactone, peppermint and rosemary oils, and saw palmetto. The user also considers ordering RU58841 from China but finds it too expensive.
How androgens, including testosterone, can cause hair follicles to miniaturize in people with sensitivity to androgens, and treatments such as finasteride, dutasteride, minoxidil, RU58841, or fluridil may be used in combination for long-term treatment.
The post and conversation are about HMI-115, a potential treatment for hair loss. The conclusion is that HMI-115 is not a 5ar-inhibitor and is instead a prolactin receptor inhibitor. Some users are skeptical about its effectiveness and believe that baldness will still be a problem in the future.
The conversation discusses the potential of developing a selective oral SARM to target androgen activity in the scalp and skin, as an alternative to oral Dutasteride and Finasteride, which have systemic side effects. It also mentions Clascoterone and RU58841 as topical treatments for hair loss.
The possible increased risk of severe Covid-19 cases in men due to higher androgen levels, and how taking medications such as finasteride, dutasteride, spironolactone, enzalutamide, or canabidiol might help mitigate the severity of the disease.
NMN shows promise in promoting hair growth by reducing oxidative stress and weakening androgens. It may be a beneficial addition to hair loss treatments like Minoxidil and Finasteride.